Clinical Trials Logo

Dedifferentiated Liposarcoma clinical trials

View clinical trials related to Dedifferentiated Liposarcoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06389799 Not yet recruiting - Clinical trials for Dedifferentiated Liposarcoma

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

PERELI
Start date: May 7, 2024
Phase: Phase 2
Study type: Interventional

Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improved by combining it with other types of tumor drugs. Medicines that inhibit signaling via the FGF receptor, so-called FGFR inhibitors, have shown a tumor-slowing effect in DDLPS in early studies. FGFR inhibitors can also induce changes that make the tumor more available to treatment with immunotherapy. The study aims to investigate whether the combination of an FGFR inhibitor, pemigatinib, with a PD-1 inhibitor, retifanlimab can provide a tumor-slowing effect in patients with advanced DDLPS who have progressed on first-line treatment.

NCT ID: NCT05496569 Not yet recruiting - Clinical trials for Dedifferentiated Liposarcoma

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

Start date: December 2022
Phase: Phase 2
Study type: Interventional

A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.